



IBA Signs Contract to Install its Compact Proton Therapy System Proteus[®]ONE at Beaumont Health System, USA

Louvain-la-Neuve, Belgium, 20 November, 2014 - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces today that it has signed a contract with Beaumont Health System for the installation in Royal Oak, Michigan, USA, of its compact single-room proton therapy system Proteus[®]ONE*. The contract signature follows the FDA's approval of IBA's compact gantry system in July.

The contract includes delivery of the Proteus[®]ONE equipment as well a long term maintenance agreement. The typical end-user price for the Proteus[®]ONE proton therapy system with a 10 year maintenance contract totals between EUR 35 and 40 million. This contract will be the sixth installation of a Proteus[®]ONE, the 29th IBA proton therapy facility worldwide and the 13th in North America. The center is expected to treat its first patient in 2017.

Olivier Legrain, Chief Executive Officer of IBA commented: "Since receiving the marketing authorization from the FDA for our new compact gantry, we have seen a heightened interest in our market leading compact offering, Proteus[®]ONE. Beaumont's choice of IBA not only reflects the strong profile of Proteus[®]ONE compared to other compact offerings, but also the preference of IBA as the most experienced and fastest proton therapy provider in the market. We look forward to working closely with Beaumont to bring the superior benefits of proton therapy to more patients in the USA."

Craig Stevens, M.D., Chair, Radiation Oncology, Beaumont Health System commented: "The proton therapy facility will provide our team of oncologists another critical tool in the fight against cancer. Proton therapy will bring a new level of cancer care to patients in the region."

Proton International, a USA based proton therapy project management company, will support the Beaumont Health System team in business planning, building design, project management, training, and ongoing support of operations.

Chris Chandler, Chief Executive Officer of Proton International commented: "Our team is pleased to be a part of this important project, we look forward to assisting in the successful completion of this facility by augmenting the strength of the IBA and Beaumont teams with our experience in proton therapy development."

- ENDS -



Notes to Editors

About Proteus[®]ONE

Proteus[®]ONE is the compact intensity modulated proton therapy (IMPT) solution from IBA. It benefits from the latest technologies developed with renowned clinical institutions. Proteus[®]ONE is smaller, more affordable, easier to install and to operate. It is ultimately easier to finance, making this advanced radiation therapy modality available to more institutions and patients worldwide. Proteus[®]ONE makes Proton Therapy easy.

** Proteus[®]ONE is the brand name of a new configuration of the Proteus[®]235*

About Proton Therapy

Proton Therapy is considered the most advanced and targeted cancer treatment due to its superior dose distribution and fewer side effects. Protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumor, sparing healthy surrounding tissue. Higher doses can be delivered to the tumor without increasing the risk of side effects and long-term complications, thereby improving patient outcomes and quality of life.

About IBA

IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment equipment company, and the worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy available today.

The Company's primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and equipment. IBA's proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centers as well as next generation compact, single room solutions. IBA also focuses on the development and supply of dosimetry solutions for Quality Assurance of medical equipment and increased patient safety as well as particle accelerators for medical and industrial applications.

Headquartered in Belgium and employing about 1000 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors, providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange Euronext. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

About Beaumont Health System

Beaumont Health System's cancer program combines the expertise of surgical, medical and radiation oncologists to offer cancer prevention counseling, diagnosis and treatment in hospital and community-based settings. The Beaumont Cancer Institute is one of only 34 community sites in the U.S. to be awarded a five-year National Cancer Institute Community Oncology Research Program grant. Beaumont is designated as a Blue Cross Center of Distinction for the Treatment of Rare and Complex

Press release |

Regulated information



Cancers. Beaumont, Royal Oak and Troy are recognized by U.S. News & World Report as “high performing” hospitals for cancer care. Find out more at <http://cancer.beaumont.edu/>.

About Proton International

Proton International is a project oriented proton therapy development company providing innovative and experienced based development and operational services. Team members have successfully developed multiple proton centers with our services focused on business planning, design, financing, equipment selection, project management, training, and ongoing support of operations.

www.protonintl.com

For further information please contact:

IBA

Jean-Marc Bothy
Chief Financial Officer
+32 10 475 890

Investorrelations@iba-group.com

Thomas Ralet
Vice-President Corporate Communication
+32 10 475 890

thomas.ralet@iba-group.com

For media and investor enquiries:

Consilium Strategic Communications

Amber Bielecka, Mary-Jane Elliott, Matthew Neal, Jessica Hodgson and Ivar Milligan
+44 (0) 203 709 5700

IBA@consilium-comms.com

Proton International

Chris Chandler
Chief Executive Officer

cchandler@protonintl.com